ProQR Therapeutics (PRQR) EBIT Margin (2021 - 2026)
ProQR Therapeutics (PRQR) posted EBIT Margin of 671.37% for Q1 2026, down 245.98% sequentially from 194.05% in Q4 2025, and down 43203.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
ProQR Therapeutics (PRQR) EBIT Margin (2021 - 2026) Analysis & Trends
ProQR Therapeutics has reported EBIT Margin for 14 years, with the latest figure at 671.37% in Q1 2026.
- Quarterly EBIT Margin fell 43203.0% year-over-year to 671.37% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 345.37% (down 17058.0% YoY) and the FY2025 annual result came in at 273.14%, down 11196.0% from the prior year.
- EBIT Margin slipped to 671.37% in Q1 2026 per PRQR's latest filing, from 194.05% in the prior quarter.
- Over five years, EBIT Margin peaked at 57.1% in Q2 2024 and troughed at 2435.26% in Q3 2022.
- A 5-year average of 752.24% and a median of 391.53% in 2025 frame the typical range for EBIT Margin.
- The widest YoY moves for EBIT Margin: up 551965 bps in 2022, down 140832 bps in 2022.
- Over 5 years, EBIT Margin stood at 1730.56% in 2022, then soared by 89 bps to 190.86% in 2023, then retreated by 23 bps to 234.06% in 2024, then climbed by 17 bps to 194.05% in 2025, then sank by 246 bps to 671.37% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 671.37%, 194.05%, and 391.53% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | ProQR Therapeutics | 218.57 Mn | 82.18 Mn | - | -100.72% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -100.72% |
| Mar 31, 2026 | -671.37% |
| Dec 31, 2025 | -190.23% |
| Sep 30, 2025 | -391.53% |
| Jun 30, 2025 | -320.91% |
| Mar 31, 2025 | -239.34% |
| Dec 31, 2024 | -234.06% |
| Sep 30, 2024 | -226.80% |
| Jun 30, 2024 | -57.10% |
| Mar 31, 2024 | -181.46% |
| Dec 31, 2023 | -190.86% |
| Sep 30, 2023 | -539.49% |
| Jun 30, 2023 | -731.20% |
| Mar 31, 2023 | -1,433.44% |
| Dec 31, 2022 | -1,730.56% |
| Sep 30, 2022 | -2,435.26% |
| Jun 30, 2022 | -1,702.37% |
| Mar 31, 2022 | -1,508.32% |
| Dec 31, 2021 | -7,250.21% |
| Sep 30, 2021 | -1,669.38% |